• 1. Exciplex emission from the mixed dimer of naphthalene and 2-cyanonaphthalene in a supersonic jet
  Aloke Das,K. K. Mahato,Chayan K. Nandi,Tapas Chakraborty,Shridhar R. Gadre,Nikhil A. Gokhale Phys. Chem. Chem. Phys., 2002,4, 2162-2168
• 2. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 3. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
• 4. Estimation of activation energy for electroporation and pore growth rate in liquid crystalline and gel phases of lipid bilayers using molecular dynamics simulations?
  Amit Kumar Majhi,Subbarao Kanchi,V. Venkataraman,K. G. Ayappa,Prabal K. Maiti Soft Matter, 2015,11, 8632-8640
• 5. Fe3O4 nanoparticle chains with N-doped carbon coating: magnetotactic bacteria assisted synthesis and high-rate lithium storage?
  Dan Yang,Yanping Zhou,Xianhong Rui,Jixin Zhu,Ziyang Lu,Eileen Fong,Qingyu Yan RSC Adv., 2013,3, 14960-14962

Recent Advances in the Application of 5-Bromo-1H-pyrrolo[2,3-b]pyridine-6-carboxylic acid (CAS: 1190322-26-9) in Chemical Biology and Pharmaceutical Research

The compound 5-Bromo-1H-pyrrolo[2,3-b]pyridine-6-carboxylic acid (CAS: 1190322-26-9) has recently emerged as a key intermediate in the synthesis of novel bioactive molecules, particularly in the development of kinase inhibitors and other targeted therapeutics. This heterocyclic scaffold has garnered significant attention due to its versatility in medicinal chemistry and its potential applications in treating various diseases, including cancer and inflammatory disorders. Recent studies have explored its role as a building block for more complex pharmacophores, leveraging its unique electronic and steric properties.

In a 2023 study published in the Journal of Medicinal Chemistry, researchers demonstrated the utility of 5-Bromo-1H-pyrrolo[2,3-b]pyridine-6-carboxylic acid in the synthesis of selective JAK2 inhibitors. The bromo-substituted pyrrolopyridine core was found to enhance binding affinity and selectivity, with the carboxylic acid moiety facilitating further derivatization. The study highlighted the compound's role in improving pharmacokinetic properties, such as solubility and metabolic stability, which are critical for drug development.

Another significant application was reported in a 2024 Nature Communications paper, where the compound served as a precursor for the development of PROTACs (Proteolysis Targeting Chimeras). The researchers utilized its reactive sites to conjugate with E3 ligase ligands, enabling the targeted degradation of oncogenic proteins. This approach showcased the molecule's potential in next-generation therapeutic strategies, particularly in overcoming drug resistance in cancer treatment.

From a synthetic chemistry perspective, recent advancements in transition-metal-catalyzed cross-coupling reactions have expanded the utility of 5-Bromo-1H-pyrrolo[2,3-b]pyridine-6-carboxylic acid. A 2023 ACS Catalysis publication detailed a novel palladium-catalyzed arylation protocol that allows for efficient functionalization of the bromo position while preserving the carboxylic acid group. This methodological breakthrough has significantly streamlined the synthesis of diverse pyrrolopyridine-based libraries for high-throughput screening.

Ongoing research is exploring the compound's potential in radiopharmaceutical applications. Preliminary studies presented at the 2024 SNMMI Annual Meeting demonstrated its suitability as a precursor for ¹⁸F-labeled PET tracers, owing to the favorable leaving group characteristics of the bromo substituent. This development could open new avenues in diagnostic imaging for neurological disorders and certain cancers.

As the pharmaceutical industry continues to prioritize targeted therapies and personalized medicine, 5-Bromo-1H-pyrrolo[2,3-b]pyridine-6-carboxylic acid (CAS: 1190322-26-9) is poised to play an increasingly important role in drug discovery pipelines. Its unique structural features and demonstrated versatility across multiple therapeutic modalities make it a valuable asset in contemporary medicinal chemistry efforts. Future research directions may focus on expanding its applications in covalent inhibitor design and as a scaffold for bifunctional molecules in chemical biology.

• 61830-12-4(2,6-Pyridinedicarboxylic acid, 3,5-dibromo-)
• 889939-41-7(6-BROMO-3H-IMIDAZO[4,5-B]PYRIDINE-5-CARBOXYLIC ACID)
• 61830-40-8(3,5-Dibromopicolinic acid)
• 1189933-55-8(3-Bromopicolinic Acid Sodium Salt)
• 1204475-66-0(1H-Pyrrolo[2,3-b]pyridine-2-carboxylic acid, 3-bromo-)
• 30683-23-9(3-Bromopyridine-2-carboxylic acid)
• 779344-30-8(3-bromo-6-methylpyridine-2-carboxylic acid)
• 137778-20-2(5-bromo-6-methyl-pyridine-2-carboxylic acid)
• 1204476-06-1(1H-Pyrrolo[2,3-b]pyridine-2-carboxylic acid, 3-bromo-4-hydroxy-)
• 316808-10-3(3-Bromopyridine-2,6-dicarboxylic acid)